Wnt/β-catenin signaling pathway and cancer stem cells

doi:10.3760/cma.j.issn.1673-422X.2017.11.012

Abstract

Abstract: Adult stem cells play important roles in the regeneration of human tissues, and they form cancer stem cells when malignant transformation occurs. Cancer stem cells are closely related to the occurrence of various tumors, chemotherapy resistance and recurrence. The Wnt/βcatenin signaling pathway regulates embryonic development and is evolutionarily conserved, and plays an important role in selfrenewal and differentiation of cancer stem cells. The Wnt/βcatenin signaling pathway and related regulatory proteins have become a hot target for cancer stem cell targeted therapy.

Key words: Neoplastic stem cells, Therapy, Wnt/β-catenin signaling pathway

郑佩. Wnt/β-catenin signaling pathway and cancer stem cells[J]. Journal of International Oncology, 2017, 44(11): 853-855.

References

［1］ Lenz HJ, Kahn M. Safely targeting cancer stem cells via selective catenin coactivator antagonism［J］. Cancer Sci, 2014, 105(9): 1087-1092. DOI: 10.1111/cas.12471. ［2］Li Y, Zhang T. Targeting cancer stem cells by curcumin and clinical applications［J］. Cancer Lett, 2014, 346(2): 197-205. DOI: 10.1016/j.canlet.2014.01.012. ［3］Voronkov A, Krauss S. Wnt/betacatenin signaling and small molecule inhibitors［J］. Curr Pharm Des, 2013, 19(4): 634-664. ［4］Lamb R, Ablett MP, Spence K, et al. Wnt pathway activity in breast cancer subtypes and stemlike cells［J］. PLos One, 2013, 8(7): e67811. DOI: 10.1371/journal.pone.0067811. ［5］Cai WY, Wei TZ, Luo QC, et al. The Wntβcatenin pathway represses let-7 microRNA expression through transactivation of Lin28 to augment breast cancer stem cell expansion［J］. J Cell Sci, 2013, 126(Pt 13): 2877-2889. DOI: 10.1242/jcs.123810. ［6］Zhao Z, Lu P, Zhang H, et al. Nestin positively regulates the Wnt/βcatenin pathway and the proliferation, survival and invasiveness of breast cancer stem cells［J］. Breast Cancer Res, 2014, 16(4): 408. DOI: 10.1186/s1305801404088. ［7］Fu Y, Chang H, Peng X, et al. Resveratrol inhibits breast cancer stemlike cells and induces autophagy via suppressing Wnt/βcatenin signaling pathway［J］. PLoS One, 2014, 9(7): e102535. DOI: 10.1371/journal.pone.0102535. ［8］Jang GB, Hong IS, Kim RJ, et al. Wnt/βcatenin smallmolecule inhibitor CWP232228 preferentially inhibits the growth of breast cancer stemlike cells［J］. Cancer Res, 2015, 75(8): 1691-1702. DOI: 10.1158/00085472.CAN-14-2041. ［9］Krausova M, Korinek V. Wnt signaling in adult intestinal stem cells and cancer［J］. Cell Signal, 2014, 26(3): 570579. DOI: 10.1016/j.cellsig.2013.11.032. ［10］ Roy S, Majumdar AP. Signaling in colon cancer stem cells［J］. J Mol Signal, 2012, 7(1): 11. DOI: 10.1186/17502187711. ［11］ Kemper K, Prasetyanti PR, De Lau W, et al. Monoclonal antibodies against Lgr5 identify human colorectal cancer stem cells［J］. Stem Cells, 2012, 30(11): 2378-2386. DOI: 10.1002/stem.1233. ［12］ Moon BS, Jeong WJ, Park J, et al. Role of oncogenic KRas in cancer stem cell activation by aberrant Wnt/βcatenin signaling［J］. J Natl Cancer Inst, 2014, 106(2): djt373. DOI: 10.1093/jnci/djt373. ［13］ Zhang T, Wang K, Zhang J, et al. Huaier aqueous extract inhibits colorectal cancer stem cell growth partially via downregulation of the Wnt/βcatenin pathway［J］. Oncol Lett, 2013, 5(4): 11711176. DOI: 10.3892/ol.2013.1145. ［14］ Gong A, Huang S. FoxM1 and Wnt/βcatenin signaling in glioma stem cells［J］. Cancer Res, 2012, 72(22): 5658-5662. DOI: 10.1158/00085472.CAN-12-0953. ［15］ Sandberg CJ, Altschuler G, Jeong J, et al. Comparison of glioma stem cells to neural stem cells from the adult human brain identifies dysregulated Wnt signaling and a fingerprint associated with clinical outcome［J］. Exp Cell Res, 2013, 319(14): 22302243. DOI: 10.1016/j.yexcr.2013.06.004. ［16］ Kim KH, Seol HJ, Kim EH, et al. Wnt/βcatenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells［J］. Neuro Oncol, 2013, 15(2): 161-171. DOI: 10.1093/neuonc/nos299. ［17］ Rathod SS, Rani SB, Khan M, et al. Tumor suppressive miRNA34a suppresses cell proliferation and tumor growth of glioma stem cells by targeting Akt and Wnt signaling pathways［J］. FEBS Open Bio, 2014, 4: 485-495. DOI: 10.1016/j.fob.2014.05.002. ［18］ Chen W, Zhang YW, Li Y, et al. Constitutive expression of Wnt/βcatenin target genes promotes proliferation and invasion of liver cancer stem cells［J］. Mol Med Rep, 2016, 13(4): 3466-3474. DOI: 10.3892/mmr.2016.4986. ［19］ Wang Y, He L, Du Y, et al. The long noncoding RNA lncTCF7 promotes selfrenewal of human liver cancer stem cells through activation of Wnt signaling［J］. Cell Stem Cell, 2015, 16(4): 413-425. DOI: 10.1016/j.stem.2015.03.003. ［20］ Gedaly R, Galuppo R, Daily MF, et al. Targeting the Wnt/βcatenin signaling pathway in liver cancer stem cells and hepatocellular carcinoma cell lines with FH535［J］. PLoS One, 2014, 9(6): e99272. DOI: 10.1371/journal.pone.0099272. ［21］ Galuppo R, Maynard E, Shah M, et al. Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/βcatenin pathways［J］. Anticancer Res, 2014, 34(4): 1709-1713. ［22］ Zhang Y, Zhang X, Huang J, et al. Wnt signaling regulation of stemlike properties in human lung adenocarcinoma cell lines［J］. Med Oncol, 2015, 32(5): 157. DOI: 10.1007/s12032015-0596-9. ［23］ Yeh CT, Wu AT, Chang PM, et al. Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer［J］. Am J Respir Crit Care Med, 2012, 186(11): 11801188. DOI: 10.1164/rccm.2012071180OC. ［24］ Fang L, Cai J, Chen B, et al. Aberrantly expressed miR5823p maintains lung cancer stem celllike traits by activating Wnt/βcatenin signalling［J］. Nat Commun, 2015, 6: 8640. DOI: 10.1038/ncomms9640. ［25］ Mao J, Fan S, Ma W, et al. Roles of Wnt/βcatenin signaling in the gastric cancer stem cells proliferation and salinomycin treatment［J］. Cell Death Dis, 2014, 5: e1039. DOI: 10.1038/cddis.2013.515. ［26］ Lee SH, Koo BS, Kim JM, et al. Wnt/βcatenin signalling maintains selfrenewal and tumourigenicity of head and neck squamous cell carcinoma stemlike cells by activating Oct4［J］. J Pathol, 2014, 234(1): 99107. DOI: 10.1002/path.4383. ［27］ Hsieh IS, Chang KC, Tsai YT, et al. MicroRNA320 suppresses the stem celllike characteristics of prostate cancer cells by downregulating the Wnt/β-catenin signaling pathway［J］. Carcinogenesis, 2013, 34(3): 530538. DOI: 10.1093/carcin/bgs371. ［28］ Ono M, Yin P, Navarro A, et al. Paracrine activation of WNT/β-catenin pathway in uterine leiomyoma stem cells promotes tumor growth［J］. Proc Natl Acad Sci USA, 2013, 110(42): 1705317058. DOI: 10.1073/pnas.1313650110. ［29］ Wu G, Liu A, Zhu J, et al. MiR1207 overexpression promotes cancer stem celllike traits in ovarian cancer by activating the Wnt/βcatenin signaling pathway［J］. Oncotarget, 2015, 6(30): 28882-28894. DOI: 10.18632/oncotarget.4921. ［30］ Lin LC, Yeh CT, Kuo CC, et al. Sulforaphane potentiates the efficacy of imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt/βcatenin function［J］. J Agric Food Chem, 2012, 60(28): 7031-7039. DOI: 10.1021/jf301981n.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[4]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[5]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[6]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[7]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[8]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311.
[9]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[10]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[11]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[12]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[13]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[14]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[15]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.